Several AD therapies under investigation target Aβ or its aggregates and can generally be divided into four therapeutic aims: 1) to reduce Aβ generation; 2) to enhance degradation and clearance of Aβ and its aggregates; 3) to neutralize soluble Aβ monomers or the resulting toxicity; 4) to directly inhibit Aβ aggregation.1 As of August 2023, aducanumab and lecanemab are the only two FDA approved antibody-based drugs, while investigation of 38 therapies have been discontinued due to ineffectiveness or toxic side effects.1-3

Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.

file_download Download in HQ

Related content

image Image The pathology of ischaemic stroke is complex, but commonly involves the formation of a clot that travels in the blood to or within the brain and becomes lodged in the blood vessels of the brain (a thromboembolism), which can reduce or block blood flow (an occlusion).
Pathology of Ischaemic Stroke

The pathology of ischaemic stroke is complex, but commonly involves the formation of a clot that travels in the blood to or within the brain and becomes lodged in the blood vessels of the brain (a thromboembolism), which can reduce or block blood flow (an occlusion).

22.04.2024 Neurobehavioral Consequences of Stroke
image Image Post-stroke neuropsychiatric symptoms (NPS) - Fatigue
Post-stroke Neuropsychiatric Symptoms (NPS) – Fatigue

Post-stroke fatigue is an under-recognized NPS, which healthcare professionals should anticipate in patients.

22.04.2024 Neurobehavioral Consequences of Stroke
image Image Brain circuitry and emotional lability
Brain Circuitry and Emotional Lability

Emotional lability describes episodes of involuntary and uncontrollable crying and/or laughing, outside of socially appropriate circumstances and when it is incongruent with the patient’s emotional state.

22.04.2024 Neurobehavioral Consequences of Stroke